PYGO2 (F7N8Z) Rabbit mAb #83034
- WB
- IP
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 50-60 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Genetic studies have shown PYGO2 as a component of canonical Wnt signaling (1-3). With a highly conserved plant homeodomain (PHD) in its C-terminus, PYGO2 binds epigenetic marks and activates gene expression. Evidence suggests that PYGO2 modulates transcription through both Wnt and Notch pathways (2-3). Dysregulation and increased expression of PYGO2 have been observed in several malignancies: breast (4,5), ovarian, colon (6,7), and prostate (8,9).
The role of PYGO2 in immuno-oncology is being actively investigated. Loss of PYGO2 results in increased activation and infiltration of cytotoxic T lymphocytes (CTLs) and sensitizes tumor cells to killing (9). Increased PYGO2 has been shown to result in an aberrant tumor microenvironment hostile to CTLs. Pharmacological targeting of PYGO2 enhances the efficacy of immunotherapies when combined with immune checkpoint blockade (ICB) (9).
- Horsley, V. (2009) J Cell Biol 185, 761-3.
- Schwab, K.R. et al. (2007) BMC Biol 5, 15.
- Gu, B. et al. (2013) Cell Stem Cell 13, 48-61.
- Zhang, Z.M. et al. (2016) Oncogene 35, 4787-97.
- Saxena, M. et al. (2020) Cancer Res 80, 3631-3648.
- Talla, S.B. and Brembeck, F.H. (2016) Oncotarget 7, 80612-80632.
- Soleymani, S. et al. (2019) J Histotechnol 42, 98-103.
- Lu, X. et al. (2018) Cancer Res 78, 3823-3833.
- Zhu, Y. et al. (2023) Sci Immunol 8, eade4656.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.